XML 74 R16.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Note 10 - Equity Incentive Plan | 12 Months Ended
--- | ---
Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] |
Disclosure of Compensation Related Costs, Share-based Payments [Text Block] | 10. Equity Incentive Plan The Anika Therapeutics, Inc. Stock Option and Incentive Plan, as amended, (the “2003 Plan”) provides for grants of nonqualified and incentive stock options, common stock, restricted stock, restricted stock units, and stock appreciation rights (“SAR’s”) to employees, directors, officers and consultants. The 2003 Plan was originally approved by the Board of Directors on April 4, 2003, approved by the Company’s shareholders on June 4, 2003, and reserved 1,500,000 shares of common stock for grant pursuant to its terms. On May 29, 2009, the Board of Directors approved changes to the 2003 Plan and adopted the Amended and Restated 2003 Stock Option and Incentive Plan (the “Amended 2003 Plan”), to increase the number of shares available to grant by 850,000. The Amended 2003 Plan was approved by the Company’s shareholders on June 5, 2009, and resulted in a total of 2,350,000 shares of common stock being reserved for issuance under the Amended 2003 Plan. At the 2011 Annual Meeting of Stockholders on June 7, 2011, the shareholders of the Company approved the Anika Therapeutics, Inc. Second Amended and Restated Stock Option and Incentive Plan (the “2003 Plan”), which, among other things, increased the number of shares reserved for issuance under the Company’s predecessor stock option and incentive plan by 800,000 to 3,150,000 shares. At the 2013 Annual Meeting of Stockholders on June 18, 2013, the shareholders of the Company approved an additional amendment to the Amended 2003 Plan, which among other things, increased the number of shares reserved for issuance under the Company’s stock option and incentive plan by 650,000 to 3,800,000 shares. The Company may satisfy the awards upon exercise, or upon fulfillment of the vesting requirements for other equity-based awards, with either newly-issued shares or shares reacquired by the Company. Stock-based awards are granted with an exercise price equal to the market price of the Company’s stock on the date of grant. Awards contain service or performance conditions and generally become exercisable ratably over one to four years. The 2003 Plan succeeds the Anika Therapeutics, Inc. 1993 Stock Option Plan (“1993 Plan”) which expired according to its terms in 2003. As of December 31, 2013, there were no shares outstanding under the 1993 Plan included in the total outstanding options of 1,513,326. There are 1,266,036 options available for future grant at December 31, 2013. The Company estimates the fair value of stock options and SAR’s using the Black-Scholes valuation model. Fair value of restricted stock is measured by the grant-date price of the Company’s shares. Key input assumptions used to estimate the fair value of stock options and SAR’s include the exercise price of the award, the expected award term, the expected volatility of the Company’s stock over the option’s expected term, the risk-free interest rate over the award’s expected term, and the Company’s expected annual dividend yield. The Company uses historical data on exercise of stock options and other factors to evaluate and estimate the expected term of share-based awards. The Company also evaluates actual forfeiture rates periodically and adjusts the expected forfeiture rate assumption within the model accordingly. The expected volatility assumption is evaluated against the historical volatility of the Company’s common stock over a four year average and is adjusted if there are material swings in historical volatility. The risk-free interest rate assumption is based on U.S. Treasury interest rates at the time of grant. The fair value of each stock option and SAR award during 2013, 2012, and 2011 was estimated on the grant date using the Black-Scholes option-pricing model with the following assumptions:
|  | December 31,
|  | 2013 |  | 2012 |  | 2011
Risk free interest rate |  | 0.61% | to | 1.02% |  | 0.63% | to | 0.64% |  | 1.1% | to | 1.51%
Expected volatility |  | 53.6% | to | 57.6% |  |  | 57.60% |  |  |  | 57.60% |
Expected lives (years) |  |  | 4 |  |  |  | 4 |  |  |  | 4 |
Expected dividend yield |  |  | 0.00% |  |  |  | 0.00% |  |  |  | 0.00% |
The Company recorded $1,268,070, $1,151,199 and $1,190,697 of share-based compensation expense for the years ended December 31, 2013, 2012 and 2011, respectively, for stock options, SAR’s and restricted stock awards. The Company presents the expenses related to stock-based compensation awards in the same expense line items as cash compensation paid to each of its employees. Combined stock options and SAR’s activity under our plans is summarized as follows for the years ended December 31, 2013 and, 2012 respectively:
|  | 2013 |  |  | 2012 |
|  | Number of Shares |  |  | Weighted Average Exercise Price Per Share |  |  | Number of Shares |  |  | Weighted Average Exercise Price Per Share |
Options and SAR's outstanding at beginning of year |  |  | 1,793,685 |  |  | $ | 8.30 |  |  |  | 2,108,003 |  |  | $ | 7.26 |
Granted |  |  | 413,500 |  |  | $ | 12.55 |  |  |  | 204,000 |  |  | $ | 12.06 |
Cancelled |  |  | (243,724 | ) |  | $ | 8.77 |  |  |  | (212,749 | ) |  | $ | 6.58 |
Expired |  |  | (9,928 | ) |  | $ | 9.62 |  |  |  | (7,714 | ) |  | $ | 1.68 |
Exercised |  |  | (440,207 | ) |  | $ | 8.71 |  |  |  | (297,855 | ) |  | $ | 4.74 |
Options and SAR's outstanding at end of year |  |  | 1,513,326 |  |  | $ | 9.14 |  |  |  | 1,793,685 |  |  | $ | 8.30 |
Of the 1,513,326 options and SAR’s outstanding at December 31, 2013, 1,484,786 are vested, or are expected to vest, with a weighted-average exercise price of approximately $7.87 as well as an aggregate intrinsic value of approximately $28 million related to these awards. The weighted average remaining contractual term of the vested and expected to vest options and SAR’s was 4.1 years as of December 31, 2013. As of December 31, 2013, total unrecognized compensation costs related to non-vested options and SAR’s was approximately $1,974,000 and is expected to be recognized over a weighted average period of 2.9 years. There were 198,989 incentive stock options exercisable at December 31, 2013 with a weighted-average exercise price of $8.56 and a weighted-average remaining contractual term of 5.2 years for these awards. There were 152,968 non-qualified stock options exercisable at December 31, 2013 with a weighted-average exercise price of $8.43 and a weighted-average remaining contractual term of 5.2 years. There were 572,453 SAR’s exercisable at December 31, 2013 with a weighted-average exercise price of $7.49 and a weighted-average remaining contractual term of 3.4 years for these awards. The aggregate intrinsic value of stock options and SAR’s fully vested at December 31, 2013 and 2012 was $27,997,198 and $2,115,267, respectively. The aggregate intrinsic value of stock options and SAR’s outstanding at December 31, 2013 and, 2012 was $43,199,713 and $4,074,471, respectively. The total intrinsic value of options and SAR’s exercised was $4,370,830 and, $2,214,516 for the years ended December 31, 2013 and 2012, respectively. The total fair value of options and SAR’s vested during the years ended December 31, 2013 and 2012 was $1,088,802 and $997,194, respectively. The Company received $3,053,941 and $388,675 for exercises of stock options during the years ended December 31, 2013 and 2012, respectively. The restricted stock activity for the years ended December 31, 2013 and 2012 is as follows:
|  | 2013 |  |  | 2012 |
|  | Number of Shares |  |  | Weighted Average Granted Date Fair Value |  |  | Number of Shares |  |  | Weighted Average Granted Date Fair Value |
Nonvested at Beginning of year |  |  | 68,956 |  |  | $ | 6.87 |  |  |  | 59,196 |  |  | $ | 5.71 |
Granted |  |  | 36,220 |  |  | $ | 17.00 |  |  |  | 31,312 |  |  | $ | 9.10 |
Cancelled |  |  | - |  |  | $ | - |  |  |  | (25 | ) |  | $ | 3.05 |
Expired |  |  | - |  |  | $ | - |  |  |  | - |  |  | $ | - |
Vested/Released |  |  | (25,585 | ) |  | $ | 5.95 |  |  |  | (21,527 | ) |  | $ | 5.08 |
Nonvested at end of year |  |  | 79,591 |  |  | $ | 11.93 |  |  |  | 68,956 |  |  | $ | 6.87 |
The total fair value of restricted stock and restricted stock units vested during the year ended December 31, 2013 was $290,704.

X
- Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 40 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration